Biossil acquires Theriva antibiotic-degrading enzyme portfolio with up to $91 million in milestones
Biossil Labs has acquired Theriva Biologics' antibiotic-degrading enzyme portfolio, including Phase IIb-stage ribaxamase, in an asset transaction carrying up to $91 million in contingent milestones.
The completed acquisition announced on 2 November 2026 transfers SYN-004 (ribaxamase), SYN-007 and specified SYN-006 assets to Biossil, which will assume future development and commercialisation responsibilities for programmes targeting antibiotic-associated microbiome disruption and related complications.
Theriva received $350,000 upfront at closing and remains eligible for up to $3 million in regulatory milestones, $88 million in sales milestones and low-single-digit royalties subject to a $250 million cap, making the headline $91 million a contingent milestone opportunity rather than the immediate acquisition price.
Field | Content |
Article Type | Deals |
Acquirer | Biossil Labs |
Seller | Theriva Biologics |
Deal Type | Completed pharmaceutical asset acquisition |
Announcement Date | 2 November 2026 |
Transaction Status | Completed |
Acquired Portfolio | Antibiotic-degrading enzyme programmes |
Lead Programme | SYN-004 (ribaxamase) |
Lead Programme Development Stage | Phase IIb |
Additional Programme | SYN-007 |
Additional Assets | Specified SYN-006 assets |
Therapeutic Focus | Antibiotic-associated microbiome disruption and related complications |
Modality | Antibiotic-degrading enzyme therapeutics |
Upfront Consideration | $350,000 paid at closing |
Potential Regulatory Milestones | Up to $3 million |
Potential Sales Milestones | Up to $88 million |
Total Potential Milestones | Up to $91 million |
Royalty Terms | Low-single-digit royalties |
Royalty Cap | $250 million |
Development Responsibilities | Biossil assumes future development responsibilities |
Commercialisation Responsibilities | Biossil assumes future commercialisation responsibilities |
Acquisition Scope | Specified therapeutic assets; not an acquisition of Theriva Biologics |
Geographic Scope | Not confirmed in supplied summary |
What Happened | Biossil acquired Theriva's antibiotic-degrading enzyme portfolio in a completed asset sale. |
Why It Matters | The acquisition transfers clinical-stage and related enzyme programmes to a new developer pursuing approaches to protect the microbiome from antibiotic-associated disruption. |
Strategic Rationale | Advance antibiotic-degrading enzyme technologies through Biossil's development and commercialisation platform. |
Financial Clarification | The $91 million represents potential regulatory and sales milestones, not upfront acquisition consideration. |
Key Takeaway | Theriva received $350,000 at closing and may earn substantial contingent payments and royalties if Biossil advances and commercialises the acquired assets. |
What to Watch | Ribaxamase development plans, subsequent clinical studies, regulatory milestones, commercialisation progress and royalty-generating sales. |
Primary Source | Theriva Biologics |
Primary Source URL | https://therivabio.com/press_releases/theriva-biologics-announces-sale-of-syn-004-ribaxamase-and-related-antibiotic-degrading-enzyme-portfolio-to-biossil-labs-inc/ |
Relevant Date | 2 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commenti